Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

To join this study, you must be at least 18 years old and be having your very first kidney transplant, either from a living or deceased donor. You'll also need to agree to use effective birth control during the study and for about three months after you've finished taking the study medicine.

There are certain reasons why you might not be able to join. For example, if you've had a bone marrow or another organ transplant before, or if you're planning to receive more than one organ. You also can't have previously taken AT-1501 or similar medicines. The type of kidney you're receiving is also important; for instance, if it's expected to be outside the body for too long, or comes from a donor with specific medical situations.

Finally, if you have certain medical conditions, such as taking high doses of steroid medication, a history of blood clots, or if your body already has specific antibodies that could react badly to the new kidney, you won't be able to participate. This helps make sure the study is safe for everyone involved and that the results are clear.

If you decide to take part in this study, you will receive the new medicine AT-1501 along with other standard medicines given after a kidney transplant. You will have regular check-ups at the hospital or clinic. These appointments will involve blood tests to see how the medicine is working and to check for any side effects. Doctors will also closely monitor the health of your new kidney. You'll need to follow specific instructions for taking your medication and attend all scheduled visits over a certain period. The overall duration of your participation will depend on the study's design, including follow-up appointments to track your progress and long-term kidney health.